← Companies
Mind Medicine (MindMed) Inc.
Data as of Sep 17, 2026
DFTX
MNMD
CIK 1813814Lobbying
$1,050,000 in reported federal lobbying spend across 17 quarterly filings, most recently Jul 20, 2026. Amounts are the sums companies and their registrants report on Lobbying Disclosure Act filings; a filing that covers several issues counts its full amount under each.
Spend by issue
- Health Issues$1M13 filings
- Health Issues +3$20K1 filing
- Defense +3$10K1 filing
Latest filings, Jan 2026 onward
| Filed | Registrant and subject | Amount |
|---|---|---|
| Jul 20, 2026 | DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) Health Issues Lack of innovation in mental health. Need for more efficient communication/collaboration between FDA/DEA and need for VA to operationalize itself for when new therapies are approved by the FDA and rescheduled by the DEA. | $90,000 |
| Jul 20, 2026 | THE CONAFAY GROUP, LLC for DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) Health Issues Education and advocacy for novel brain health treatments. | $80,000 |
| Jul 18, 2026 | RK STRATEGIES, INC. for CLEARMIND MEDICINE INC Health Issues · Defense · Alcohol and Drug Abuse · Veterans H.R. 7091, Expanding Veterans Access to Emerging Treatments Act H.R.2623, Innovative Therapies Centers of Excellence Act of 2025 H.R. 8800, National Defense Authorization Act for Fiscal Year 2027 H.R. 9237 - Take Care of Americas Veterans A | $20,000 |
| Apr 20, 2026 | THE CONAFAY GROUP, LLC for DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) Health Issues Education and advocacy for novel brain health treatments. | $80,000 |
| Apr 15, 2026 | DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) Health Issues Lack of innovation in mental health. Need for more efficient communication/collaboration between FDA/DEA and need for VA to operationalize itself for when new therapies are approved by the FDA and rescheduled by the DEA. | $100,000 |
| Jan 20, 2026 | MIND MEDICINE (MINDMED) INC. Health Issues Lack of innovation in mental health. Need for more efficient communication/collaboration between FDA/DEA and need for VA to operationalize itself for when new therapies are approved by the FDA and rescheduled by the DEA. | $90,000 |